As you know, I have always advocating local drug delivery solutions for the ophthalmic treatments and I keep thinking that a poke in the eye (Macugen, Lucentis and other) will never be a long term solution, due to side-effects.
Since the Iomed failure in iontophoresis applied to ophthalmology back in 2002 and the total lack of progression of Aciont, it's interesting to see that a company wants to move forward with a local non-invasive drug delivery solution with iontophoresis (and convinced investors).
I checked with their technical approach at last ARVO and compared with other solutions, I can confirm I like their approach. We will see how they move forward with their funding.
Regards
Market Data 
Markets 
AI
